Arzneimittel zur Gewichtsreduktion

Zusammenfassung

Der Einsatz von Arzneimitteln zur Gewichtsreduktion wird in den Leitlinien der Deutschen Adipositas-Gesellschaft klar geregelt. Als adjuvante Therapie zusätzlich zu Interventionen bei Ernährung, Bewegung und Verhalten können sichere und wirksame Arzneimittel zur Gewichtsreduktion zur Anwendung kommen. Der Artikel fasst die Indikationsstellung zusammen und zeigt die derzeitige Situation in Deutschland auf, wo aktuell drei Arzneimittel(kombinationen) die geforderten Kriterien von Wirksamkeit und Sicherheit erfüllen (Orlistat, Liraglutid, Naltrexon+Bupropion). Weitere, nur in den USA zugelassene Arzneimittel werden beschrieben (Lorcaserin, Phentermin+Topiramat). Zuletzt wird die derzeitige Erstattungssituation in Deutschland im Bereich der gesetzlichen Krankenkassen dargestellt.

Summary

The German obesity guideline provides clear rules for the use of weight reduction drugs. Safe and efficacious drugs may be used together with interventions in eating behavior, physical activity level and psychological support in an adjuvant treatment approach. The article summarizes indications for weight reduction drugs and describes the actual situation in Germany with three drugs (or combinations) on the market fulfilling the safety and efficacy criteria (orlistat, liraglutide, naltrexon+bupropion). Weight reducing drugs only approved in the USA are also presented (lorcaserin, phentermine+topiramate). In the conclusion, the current situation of weight loss drug cost reimbursement is described.

Schlüsselwörter

Amphetamine - Aminorex - Dexfenfluramin - Lorcaserin - Phentermin - Rimonabant - Sibutramin - Topiramat - Liraglutid - Naltrexon - Bupropion

Keywords

Amphetamines - aminorex - dexfenfluramine - lorcaserin - phentermine - rimonabant - sibutramine - topiramate - liraglutide - naltrexon - bupropion

• Literatur

• 1 Interdisziplinäre Leitlinie der Qualität S3 zur “Prävention und Therapie der Adipositas”. http://www. awmf.org/leitlinien/detail/ll/050–001.html.
• 2 Toplak H, Woodward E, Yumuk V, Oppert JM, Halford JC, Frühbeck G. 2014 EASO Position Statement on the Use of Anti-Obesity Drugs. Obes Facts 2015; 08: 1666-1674.
• 3 Jones BJ, Bloom SR. The new era of drug therapy for obesity: the evidence and the expectations. Drugs 2015; 75: 935-945.
• 4 Burke LK, Heisler LK. 5-hydroxytryptamine medications for the treatment of obesity. J Neuroendocrinol 2015; 27: 389-398.
• 5 Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP. SCOUT Investigators. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523-530.
• 6 Engeli S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 2012; 209: 357-381.
• 7 Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for S. Engeli: Arzneimittel zur Gewichtsreduktion 59 the treatment of obesity. J Hypertens 2014; 32: 1178-1188.
• 8 Fachinformation Topamax® 100 mg Filmtabletten. April 2017
• 9 http://www.ema.europa.eu/docs/en_GB/docu ment_library/Summary_of_opinion_-_Initial_authorisation/human/ 002350/WC500139215.pdf.
• 10 Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of lowdose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-1352.
• 11 Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297-308.
• 12 Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014; 37: 3309-3316.
• 13 https://www.federalregister.gov/ar ticles/2012/12/19/2012-30531/schedules-of-controlled-substances-placement-of-lorcaserin-intoschedule-iv.
• 14 Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-256.
• 15 Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM. BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-3077.
• 16 O’Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 2012; 20: 1426-1436.
• 17 Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, Berry J, Camilleri M, Singh S. Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis. Gastroenterology. 2018 Jan 3. pii: S0016-5085(18)30004-0 [Epub ahead of print].
• 18 Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016; 315: 2424-2434.